Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
September 2025
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study
RMD Open 2025;11:e005742 Doi:10.1136/rmdopen-2025-005742
In this long-term extension of the Phase 2 SLEek study, Merrill et al. report that through an additional 56-weeks of treatment, upadacitinib as monotherapy or combined with elsubrutinib demonstrated sustained or improved efficacy in multiple endpoints in patients with moderately to severely active SLE.
Keywords:
May 2025
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study
Lupus Sci Med. 2025 May 6;12(1):e001484 doi: 10.1136/lupus-2024-001484
Connelly, et al. use Delphi methods to achieve consensus to include eight domains of active disease to define treatment response in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE).
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
RMD Open 2025;11:e005-444 DOI:10.1136/rmdopen-2025-005444
Padrodis et al. aimed to determine belimumab efficacy assessed using BICLA in patients with SLE included in the phase III belimumab RCTs. The benefit of belimumab was found to be more prominent when combined with anti-malarial agents. Furthermore, using BICLA, the authors validated the results from foundational trials originally assessing belimumab efficacy using SLE Responder Index 4 thus, corroborating the efficacy of #belimumab in SLE.